Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
Price:
2.7036 USD
-3.25%
Market Closed
Updated:
Apr 28, 2024
Anebulo Pharmaceuticals Inc
Net Income (Common)
|
Anebulo Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
|
Net Income (Common)
-$11.7m
|
CAGR 3-Years
-310%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income (Common)
$40.6B
|
CAGR 3-Years
39%
|
CAGR 5-Years
23%
|
CAGR 10-Years
10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income (Common)
$8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
10%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Income (Common)
$2.1B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-21%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income (Common)
$365m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
-22%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income (Common)
$5.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
1%
|
See Also
What is Anebulo Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
-11.7m
USD
-11.7m
USD
Based on the financial report for Jun 30, 2023, Anebulo Pharmaceuticals Inc's Net Income (Common) amounts to -11.7m USD.
What is Anebulo Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-310%
-310%
Over the last year, the Net Income (Common) growth was -72%. The average annual Net Income (Common) growth rates for Anebulo Pharmaceuticals Inc have been -310% over the past three years .
You don't have any saved screeners yet
